DreaMed Receives FDA Clearance for its Type 2 Diabetes AI-based Clinical Decision Support System
DreaMed Diabetes AI LTD. (“DreaMed” or the “Company”), a developer of the Advisor Pro Al Clinical Decision Support System expert-care platform for diabetes, that it has received its 4th U.S Food and Drug Administration (FDA) clearance that expands the platform's target population to patients with both type 1 and type 2 diabetes.